CD34 and sickle cell disease: In some studies, the CRISPR-Cas9 technique has been utilized to target BCL11A enhancers in CD34+ cells, which were subsequently reintroduced into patients with β-thalassemia and sickle cell disease, leading to successful treatment 52,53.